Download PDF
Kinder- und Jugendmedizin 2022; 22(05): 324-332
DOI: 10.1055/a-1908-5561
Schwerpunkt

Neue Aspekte zur Therapie des Dravet-Syndroms

New aspects for the therapy of Dravet syndrome
Susanne Schubert-Bast
1   Epilepsiezentrum Frankfurt Rhein-Main und Zentrum der Neurologie und Neurochirurgie, Goethe-Universität Franfurt, Frankfurt am Main
2   LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-Universität Frankfurt, Frankfurt am Main
3   Klinik für Kinder- und Jugendmedizin, Abt. Neuropädiatrie, Goethe-Universität Frankfurt, Frankfurt am Main
,
Adam Strzelczyk
1   Epilepsiezentrum Frankfurt Rhein-Main und Zentrum der Neurologie und Neurochirurgie, Goethe-Universität Franfurt, Frankfurt am Main
2   LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-Universität Frankfurt, Frankfurt am Main
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Das Dravet-Syndrom ist gekennzeichnet durch eine schwer behandelbare Epilepsie und assoziierte Komorbiditäten. Nun stehen neben Stiripentol mit Cannabidiol und Fenfluramin zwei neue und spezifische Therapieoptionen zur Verfügung. In diesem Beitrag erfolgt ein Überblick über die gebräuchlichsten und neuen Antikonvulsiva, deren Wirkung, Sicherheitsprofil sowie die potenziellen Interaktionen.

ABSTRACT

Dravet syndrome is characterized by drug resistant epilepsy and associated comorbidities. In addition to stiripentol, cannabidiol and fenfluramine are now available as new and specific therapeutic options. In this review, we provide an overview of the most common and new anticonvulsants, and their efficacy, safety profile, and potential interactions.

Schlüsselwörter

Dravet-Syndrom - Therapie - epileptische Enzephalopathien

Keywords

Dravet-syndrome - therapy - epileptic encephalopathy


Publication History

Article published online:
08 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG,
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Strzelczyk A, Schubert-Bast S. Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Review of Neurotherapeutics 2020: 1-15
    CrossrefPubMedSearch in Google Scholar
  • 2 Strzelczyk A, Schubert-Bast S, Bast T. et al A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia 2019; 60: 1697-1710
    CrossrefPubMedSearch in Google Scholar
  • 3 Strzelczyk A, Kurlemann G, Bast T. et al Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome. Neurol Res Pract 2022; 04: 22
    CrossrefPubMedSearch in Google Scholar
  • 4 Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52 (Suppl. 02) 3-9
    CrossrefPubMedSearch in Google Scholar
  • 5 Selvarajah A, Zulfiqar-Ali Q, Marques P. et al A systematic review of adults with Dravet syndrome. Seizure 2021; 87: 39-45
    CrossrefPubMedSearch in Google Scholar
  • 6 Shmuely S, Sisodiya SM, Gunning WB. et al Mortality in Dravet syndrome: A review. Epilepsy Behav 2016; 64: 69-74
    CrossrefPubMedSearch in Google Scholar
  • 7 Schubert-Bast S, Kay L, Simon A. et al Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data. Epilepsy Behav 2021; 126: 108442
    CrossrefPubMedSearch in Google Scholar
  • 8 Schubert-Bast S, Wolff M, Wiemer-Kruel A. et al Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature. Epilepsy Behav 2019; 98: 88-95
    CrossrefPubMedSearch in Google Scholar
  • 9 Nalivaeva NN, Belyaev ND, Turner AJ. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 2009; 30: 509-514
    CrossrefPubMedSearch in Google Scholar
  • 10 Research C for DE and. Valproate Information. FDA 2019
  • 11 Gauthier AC, Mattson RH. Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. CNS Neurosci Ther 2015; 21: 543-548
    CrossrefPubMedSearch in Google Scholar
  • 12 Frisium 10 mg Tablets – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/1574/smpc#gref Stand: 25.06.2022
  • 13 Nickels KC, Wirrell EC. Stiripentol in the Management of Epilepsy. CNS Drugs 2017; 31: 405-416
    CrossrefPubMedSearch in Google Scholar
  • 14 Fisher JL. Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines. Eur J Pharmacol 2011; 654: 160-165
    CrossrefPubMedSearch in Google Scholar
  • 15 Wirrell EC, Laux L, Franz DN. et al Stiripentol in Dravet syndrome: results of a retrospective U. S. study. Epilepsia 2013; 54: 1595-1604
    CrossrefPubMedSearch in Google Scholar
  • 16 May TW, Boor R, Mayer T. et al Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2012; 34: 390-397
    CrossrefPubMedSearch in Google Scholar
  • 17 Zulfiqar Ali Q, Marques P, Selvarajah A. et al Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine. Epilepsia 2020; 61: 2435-2441
    CrossrefPubMedSearch in Google Scholar
  • 18 Diacomit 250 mg powder for oral suspension in sachet – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/10304/smpc Stand: 25.06.2022
  • 19 Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord 2020; 22: 10-15
    CrossrefPubMedSearch in Google Scholar
  • 20 D’Onofrio G, Kuchenbuch M, Hachon-Le Camus C. et al Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study. Front Neurol 2020; 11: 829
    CrossrefPubMedSearch in Google Scholar
  • 21 Abu-Sawwa R, Stehling C. Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers. J Pediatr Pharmacol Ther 2020; 25: 75-77
    CrossrefPubMedSearch in Google Scholar
  • 22 Epidyolex 100 mg/ml oral solution – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/10781/smpc Stand: 25.06.2022
  • 23 Lattanzi S, Trinka E, Striano P. et al Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia 2020; 61: 1090-1098
    CrossrefPubMedSearch in Google Scholar
  • 24 Fintepla 2.2 mg/mL oral solution – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/11998/smpc Stand: 25.06.2022
  • 25 Schoonjans A-S, Ceulemans B. An Old Drug for a New Indication: Repurposing Fenfluramine From an Anorexigen to an Antiepileptic Drug. Clin Pharmacol Ther 2019; 106: 929-932
    CrossrefPubMedSearch in Google Scholar
  • 26 Ceulemans B, Boel M, Leyssens K. et al Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012; 53: 1131-1139
    CrossrefPubMedSearch in Google Scholar
  • 27 Boyd B, Smith S, Gammaitoni A. et al A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther 2019; 57: 11-19
    CrossrefPubMedSearch in Google Scholar
  • 28 Schoonjans A-S, Ceulemans B. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome. Expert Rev Neurother 2022; 22: 351-364
    CrossrefPubMedSearch in Google Scholar
  • 29 Martin P, de Witte PAM, Maurice T. et al Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav 2020; 105: 106989
    CrossrefPubMedSearch in Google Scholar
  • 30 Lai WW, Galer BS, Wong PC. et al Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study. Epilepsia 2020; 61: 2386-2395
    CrossrefPubMedSearch in Google Scholar
  • 31 Strzelczyk A, Pringsheim M, Mayer T. et al Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany. Epilepsia 2021; 62: 2518-2527
    CrossrefPubMedSearch in Google Scholar
  • 32 Topamax 25 mg Tablets – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/1442/smpc Stand: 25.06.2022
  • 33 Albsoul-Younes AM, Salem HA, Ajlouni SF. et al Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol 2004; 31: 349-352
    CrossrefPubMedSearch in Google Scholar
  • 34 Bast T, Steinhoff BJ.. Anticonvulsant Agents: Potassium Bromide. In: Riederer P, Laux G, Mulsant B, et al. (Hrsg). NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2020: 1-7
    Search in Google Scholar
  • 35 Lotte J, Haberlandt E, Neubauer B. et al Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics 2012; 43: 17-21
    Thieme ConnectPubMedSearch in Google Scholar